Synpromics

About Synpromics

Synpromics is a biotechnology company specializing in gene control through the development of synthetic promoters designed to improve the safety and efficacy of cell and gene therapies. The company was founded in Edinburgh, Scotland, in 2010 by Dr. Michael L. Roberts, a biochemist with extensive experience in genetic engineering. Initially, the company focused on applying its promoter technology to the agriculture and industrial biotech sectors but pivoted to gene and cell therapy due to higher demand. Dr. Roberts, serving as Chief Scientific Officer, was later joined by David Venables as CEO, a life sciences specialist who led the company through a significant growth phase.

In August 2019, Synpromics was acquired by Asklepios BioPharmaceutical, Inc. (AskBio), a US-based leader in gene therapy. It now operates as a wholly-owned subsidiary, continuing its operations in Edinburgh. This acquisition integrated Synpromics' gene regulation platform with AskBio's adeno-associated virus (AAV) delivery platform, creating a more comprehensive technology for developing highly targeted gene therapies. The collaboration aims to enhance precision control in next-generation treatments and improve the manufacturing process for AAV therapeutics.

The core of Synpromics' technology is its proprietary data-driven promoter design and bioinformatics platform, PromPT™. This platform enables the creation of custom-designed synthetic promoters, which are artificial DNA sequences that control gene activity with a high degree of selectivity. Unlike naturally occurring promoters, these synthetic versions can be engineered to activate specific genes in particular cell types, tissues, or under certain biological conditions, thereby increasing the precision and safety of therapeutic applications. The business model involves licensing its technology to pharmaceutical and biotech companies, with revenue generated through upfront fees, milestone payments, and royalties. The company has engaged in numerous commercial collaborations with partners including uniQure, Takeda, and Regeneron.